These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14619277)

  • 21. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression.
    Barnett PG; Wong W; Hall S
    Addiction; 2008 May; 103(5):834-40. PubMed ID: 18412763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user.
    Hajek P; McRobbie H; Gillison F
    Prev Med; 2007 Mar; 44(3):230-4. PubMed ID: 17207524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
    Woolacott NF; Jones L; Forbes CA; Mather LC; Sowden AJ; Song FJ; Raftery JP; Aveyard PN; Hyde CJ; Barton PM
    Health Technol Assess; 2002; 6(16):1-245. PubMed ID: 12269277
    [No Abstract]   [Full Text] [Related]  

  • 25. Does insurance coverage for drug therapy affect smoking cessation?
    Boyle RG; Solberg LI; Magnan S; Davidson G; Alesci NL
    Health Aff (Millwood); 2002; 21(6):162-8. PubMed ID: 12442851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PHARMAC and tobacco control in New Zealand: two licensed funded options are already available.
    Metcalfe S; Moodie P; McNee W
    N Z Med J; 2005 Jun; 118(1217):U1544; author reply U1544; discussion U1544. PubMed ID: 15980915
    [No Abstract]   [Full Text] [Related]  

  • 27. Should managed care organizations pay for nicotine replacement therapy?
    Westman EC
    Am J Manag Care; 1997 Feb; 3(2):335-7. PubMed ID: 10169267
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacists on the front line in providing support for nicotine replacement therapy and bupropion purchasers.
    Paul CL; Tzelepis F; Walsh RA; Turner R
    Drug Alcohol Rev; 2007 Jul; 26(4):429-33. PubMed ID: 17564880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A drug for smoking cessation?].
    Frey O
    Med Monatsschr Pharm; 2001 Jan; 24(1):24. PubMed ID: 11209732
    [No Abstract]   [Full Text] [Related]  

  • 30. [Economic evaluation of pharmacotherapies for smoking cessation].
    Antoñanzas F; Portillo F
    Gac Sanit; 2003; 17(5):393-403. PubMed ID: 14599422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buproprion, public funding, and smoking cessation.
    Bloomfield A
    N Z Med J; 2005 Jul; 118(1218):U1576. PubMed ID: 16027759
    [No Abstract]   [Full Text] [Related]  

  • 32. Developments in pharmacotherapy for tobacco dependence: past, present and future.
    Foulds J; Steinberg MB; Williams JM; Ziedonis DM
    Drug Alcohol Rev; 2006 Jan; 25(1):59-71. PubMed ID: 16492578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services.
    Bauld L; Boyd KA; Briggs AH; Chesterman J; Ferguson J; Judge K; Hiscock R
    Nicotine Tob Res; 2011 Feb; 13(2):135-45. PubMed ID: 21196451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PHARMAC and tobacco control in New Zealand: government policy 'up in smoke'.
    Holt S; Harwood M; Aldington S; Beasley R
    N Z Med J; 2005 Jun; 118(1216):U1502. PubMed ID: 15937536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of bupropion therapy for smoking cessation during routine clinical use.
    Paluck EC; McCormack JP; Ensom MH; Levine M; Soon JA; Fielding DW
    Ann Pharmacother; 2006 Feb; 40(2):185-90. PubMed ID: 16434561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smoking cessation in pregnancy: why, how, and what next..
    Crawford JT; Tolosa JE; Goldenberg RL
    Clin Obstet Gynecol; 2008 Jun; 51(2):419-35. PubMed ID: 18463471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of socioeconomic and demographic factors on the utilization of smoking cessation medications in patients hospitalized with cardiovascular disease in Nova Scotia, Canada.
    Whelan AM; Cooke CA; Sketris IS
    J Clin Pharm Ther; 2005 Apr; 30(2):165-71. PubMed ID: 15811170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-nicotine pharmacotherapies for smoking cessation.
    McRobbie H; Lee M; Juniper Z
    Respir Med; 2005 Oct; 99(10):1203-12. PubMed ID: 16011894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breaking the ties of nicotine dependence.
    Bennett SM; Andrews JO; Heath JH
    Nurse Pract; 2007 Nov; 32(11):36-45; quiz 45-6. PubMed ID: 18075457
    [No Abstract]   [Full Text] [Related]  

  • 40. Bupropion for the treatment of nicotine withdrawal and craving.
    Mooney ME; Sofuoglu M
    Expert Rev Neurother; 2006 Jul; 6(7):965-81. PubMed ID: 16831112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.